Guggenheim Reiterates Buy for ADC Therapeutics, Raises PT to $10.

Guggenheim Reiterates Buy for ADC Therapeutics, Raises PT to $10.

Guggenheim Securities has reiterated its buy rating for ADC Therapeutics SA (ADCT) and raised its price target to $10, according to a recent report [2]. The upgrade comes as the company reported its second-quarter earnings, which included a loss of $0.5 per share, surpassing the Zacks Consensus Estimate of $0.36 per share [1]. This quarterly report represents an earnings surprise of -38.89%, as the company posted a loss of $0.38 per share a year ago.

ADC Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $18.84 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.58% [1]. The company has topped consensus revenue estimates two times over the last four quarters.

The Guggenheim upgrade highlights the company's strong performance and the positive outlook for its future earnings. The analysts' rating suggests that ADC Therapeutics is expected to outperform the market in the near future. The current consensus EPS estimate is -$0.37 on $19.13 million in revenues for the coming quarter and -$1.58 on $77.93 million in revenues for the current fiscal year [1].

Investors should keep an eye on the company's earnings call for more insights into its future performance and any potential changes in its earnings outlook. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

References:
[1] https://www.nasdaq.com/articles/adc-therapeutics-sa-adct-reports-q2-loss-tops-revenue-estimates
[2] https://www.marketbeat.com/ratings/by-issuer/guggenheim-stock-recommendations/